Clinical trial · Observational
Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer
NCT04954378CI-TRIAL-00052597completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiomics | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Positive lymph node metastasis
- description
- pathological diagnosis :Positive lymph node metastasis
- interventionNames
- Diagnostic Test: radiomics
- label
- Negative lymph node metastasis
- description
- pathological diagnosis :Negative lymph node metastasis
Primary outcomes (1)
- measure
- radiomics features
- timeFrame
- After sketching the ROI
- description
- 1409 radiomics features can be extracted from the images.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * radical resection was performed, and histopathologically confirmed pancreatic ductal adenocarcinoma and lymph node status;2) CT and/or MRI enhancement examinations were performed 2 weeks before surgery;3) Patients with complete clinical data Exclusion Criteria: * (1)Patients who received radiotherapy or chemotherapy before preoperative imaging examination;2) Poor image quality.
References
Publications (0)
Data not yet available
No reference posted for this study.